Compare RENX & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RENX | RDHL |
|---|---|---|
| Founded | 2021 | 2009 |
| Country | United States | Israel |
| Employees | 38 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0M | 5.4M |
| IPO Year | N/A | 2012 |
| Metric | RENX | RDHL |
|---|---|---|
| Price | $2.05 | $1.02 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 527.8K | 39.5K |
| Earning Date | 05-22-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.09 | $0.71 |
| 52 Week High | $3.48 | $3.31 |
| Indicator | RENX | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 46.85 | 60.20 |
| Support Level | $0.12 | $0.79 |
| Resistance Level | $3.15 | $1.07 |
| Average True Range (ATR) | 0.23 | 0.06 |
| MACD | -0.11 | 0.02 |
| Stochastic Oscillator | 28.95 | 71.85 |
RenX Enterprises Corp is engaged in real property development using purpose-built, prefabricated modules constructed from both wood and steel. The Company's operations mainly focused on the acquisition, entitlement, and development of residential properties in high-growth markets across the United States. These efforts included the direct acquisition of land, strategic investments in real estate entities, and joint venture partnerships targeting green, single-family, and multifamily housing projects. The company operates into four segments as of December 31, 2025: real estate development, technology, compost sales, and logistics.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.